What's breaking now, across thousands of outlets.
Yale and Harvard medical school faculty are questioning whether the FDA and American companies will actually benefit from the US-focused incentives in the next user fee deal. Under the newly proposed
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
To defeat multidrug-resistant superbugs, bacterial defenses must be confronted wherever they may emerge, from basic genetic mutations in a laboratory to complex real-world transmission in hospital…
The Ebola Bundibugyo virus outbreak is showing initial signs of containment in the Ituri province of northeastern Democratic Republic of Congo – where it first surfaced in April.
Genomic editing holds great potential yet continues to have limitations. Current methods either rely on untargeted gene delivery or short DNA edits that need to be individualized for each patient.
A young boy with metastatic cancer was treated with an innovative immunotherapy technique, and after 12 months, the cancer appears to be completely gone.
Both the president and U.S. Health and Human Services Secretary Robert Kennedy, Jr. have made numerous false claims about the vaccines' efficacy and safety
